|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1992-11-23
|
|
pubmed:abstractText |
The purpose of this study was to determine the maximum-tolerated dose and the dose-limiting toxicities of CPT-11, a new derivative of camptothecin, in combination with a fixed dose of cisplatin in patients with non-small-cell lung cancer (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1775-80
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1328551-Adult,
pubmed-meshheading:1328551-Aged,
pubmed-meshheading:1328551-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:1328551-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1328551-Camptothecin,
pubmed-meshheading:1328551-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:1328551-Cisplatin,
pubmed-meshheading:1328551-Female,
pubmed-meshheading:1328551-Humans,
pubmed-meshheading:1328551-Lung Neoplasms,
pubmed-meshheading:1328551-Male,
pubmed-meshheading:1328551-Middle Aged,
pubmed-meshheading:1328551-Treatment Outcome
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.
|
|
pubmed:affiliation |
Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
